Gold prices slip lower; consolidating after recent gains
In a recent transaction, John Quisel, the Chief Executive Officer of Disc Medicine, Inc. (NASDAQ:IRON), sold 5,574 shares of the company’s common stock. The shares were sold at a price of $54.58 each, totaling $304,228. The transaction occurred as the stock trades near $54.35, with analysts setting price targets ranging from $73 to $118. According to InvestingPro data, IRON has shown notably volatile price movements while maintaining a GOOD financial health score. Following this transaction, Quisel retains ownership of 154,828 shares. This sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the company’s filing. With a market capitalization of $1.83 billion, Disc Medicine maintains strong liquidity, with InvestingPro analysis revealing 8 additional key insights available to subscribers, including detailed financial health metrics and growth prospects.
In other recent news, Disc Medicine has garnered attention with significant developments. Stifel analysts have raised their price target for Disc Medicine shares to $94, maintaining a Buy rating. This adjustment comes after Disc Medicine received authorization to submit a new drug application for bitopertin, aiming for accelerated approval. Stifel expressed confidence in bitopertin’s approval prospects, estimating an 85% chance and anticipating a commercial launch in 2026. Furthermore, Jefferies has maintained its Buy rating with a $111 price target, citing anticipated positive data from an upcoming presentation of DISC-0974. This presentation, scheduled for the American Society of Hematology, will include comprehensive data expected to show superior efficacy and safety results. Jefferies’ positive outlook reflects confidence in Disc Medicine’s clinical progress and its potential market impact. Disc Medicine plans to provide further details on the Phase 2 trial design during an investor event.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.